Neurocrine Bio. (NBIX) PT Lowered to $107 at Wedbush
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $137.76 -0.87%
Rating Summary:
25 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
25 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $107.00 (from $112.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
- China Telecom (728:HK) (CHA) PT Raised to HK$4.80 at HSBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
